EFG Asset Management North America Corp. Boosts Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

EFG Asset Management North America Corp. increased its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 111.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,625 shares of the biopharmaceutical company's stock after buying an additional 56,758 shares during the quarter. Insmed accounts for approximately 1.0% of EFG Asset Management North America Corp.'s holdings, making the stock its 13th biggest position. EFG Asset Management North America Corp. owned approximately 0.06% of Insmed worth $7,431,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Abel Hall LLC increased its stake in shares of Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after purchasing an additional 151 shares during the last quarter. Commerce Bank increased its stake in Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company's stock valued at $499,000 after acquiring an additional 163 shares during the period. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 163 shares during the period. M&T Bank Corp lifted its holdings in Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 166 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 183 shares during the last quarter.

Remove Ads

Insmed Stock Performance

Shares of INSM stock traded up $0.30 on Friday, hitting $77.99. 950,343 shares of the stock were exchanged, compared to its average volume of 2,230,931. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The firm has a market capitalization of $14.12 billion, a PE ratio of -13.95 and a beta of 1.28. The firm's 50 day moving average is $78.18 and its two-hundred day moving average is $73.99.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. Sell-side analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group upped their price target on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Insmed in a report on Friday, February 21st. Stifel Nicolaus cut their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Bank of America lifted their price objective on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. Finally, Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average target price of $94.00.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the sale, the insider now owns 101,549 shares of the company's stock, valued at approximately $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at approximately $25,742,347.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 550,957 shares of company stock valued at $42,992,528. Company insiders own 4.60% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.